Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Charles Conrad, MD
M.D. Anderson Cancer Center
Principal Investigator - Michael Prados, MD
University of California, San Francisco
Principal Investigator - Timothy Cloughesy, MD
University of California, Los Angeles
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California at Los Angeles
Los Angeles, California, United States
- University of California, San Francisco
San Francisco, California, United States
- the Brain Tumor Center at Duke, Duke University Medical Center
Box 3624 Dumc, Trent Drive, Durham, North Carolina, United States
- University of Texas, Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2004
- Primary completion
- 30 Nov 2005
- Completion
- 30 Nov 2005
- Last update posted
- 10 Nov 2015
- Registered enrollment
- 64
- Registry id
- NCT00116376
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.